Table 4.
Age-adjusted and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer (BC)-specific death according to race and patient characteristics among non-Hispanic white (NHW) and non-Hispanic black (NHB) women diagnosed with BC in the metropolitan Atlanta area 2010–2014 and registered with the Georgia Cancer Registry
| Characteristic | No. deaths |
Common referent HR (95% CI) |
RERI (95% CI) | Stratified effects | Stratified effects† | ||
|---|---|---|---|---|---|---|---|
| NHW | NHB | NHW | NHB | HR (95% CI) | HR (95% CI) | ||
| Insurance type* | |||||||
| Uninsured | 8 | 36 | 3.84 (1.88 to 7.84) | 6.09 (4.10 to 9.04) | 0.77 (−2.69 to 4.23) | 1.56 (0.71 to 3.43) | 1.15 (0.46 to 2.86) |
| Private insurance | 147 | 212 | Referent | 2.47 (1.98 to 3.07) | — | 2.46 (1.98 to 3.07) | 1.61 (1.28 to 2.03) |
| Medicaid | 18 | 93 | 3.18 (1.92 to 5.27) | 4.56 (3.48 to 5.97) | −0.09 (−1.92 to 1.74) | 1.44 (0.87 to 2.37) | 1.27 (0.75 to 2.16) |
| Medicare | 133 | 131 | 1.56 (1.17 to 2.07) | 3.41 (2.61 to 4.46) | 0.38 (−0.40 to 1.16) | 2.24 (1.74 to 2.90) | 1.45 (1.09 to 1.93) |
| P Interaction | .33 | .28 | |||||
| Age group, y | |||||||
| <40 | 15 | 49 | 0.66 (0.38 to 1.14) | 1.75 (1.25 to 2.46) | 0.02 (−0.72 to 0.76) | 2.68 (1.48 to 4.85) | 1.68 (0.93 to 3.03) |
| 40–49 | 39 | 102 | 0.55 (0.38 to 0.79) | 1.56 (1.20 to 2.05) | −0.06 (−0.62 to 0.49) | 2.85 (1.95 to 4.16) | 1.54 (0.99 to 2.39) |
| 50–65 | 124 | 210 | 0.65 (0.50 to 0.84) | 1.62 (1.29 to 2.04) | −0.11 (−0.61 to 0.39) | 2.50 (1.99 to 3.16) | 1.43 (1.09 to 1.86) |
| >65 | 141 | 127 | Referent | 2.08 (1.61 to 2.68) | — | 2.06 (1.60 to 2.66) | 1.35 (1.01 to 1.80) |
| P Interaction | .59 | .63 | |||||
| Marital status | |||||||
| Married | 139 | 144 | Referent | 2.82 (2.21 to 3.60) | — | 2.71 (2.13 to 3.45) | 1.79 (1.37 to 2.34) |
| Single | 47 | 170 | 1.64 (1.15 to 2.32) | 3.87 (3.05 to 4.89) | 0.41 (−0.51 to 1.33) | 2.26 (1.61 to 3.17) | 1.49 (1.03 to 2.17) |
| Divorced/widowed/separated | 116 | 143 | 1.94 (1.48 to 2.53) | 3.12 (2.44 to 3.98) | −0.64 (−1.50 to 0.21) | 1.51 (1.17 to 1.96) | 1.07 (0.79 to 1.45) |
| P Interaction | .01 | .07 | |||||
| SES index | |||||||
| 0–<5% poverty | 71 | 25 | Referent | 2.90 (1.78 to 4.73) | — | 2.67 (1.65 to 4.33) | 2.26 (1.26 to 4.06) |
| 5–<10% poverty | 96 | 57 | 1.44 (1.04 to 1.99) | 3.17 (2.20 to 4.58) | −0.16 (−1.70 to 1.37) | 2.07 (1.47 to 2.90) | 1.17 (0.76 to 1.79) |
| 10–<20% poverty | 99 | 167 | 1.61 (1.16 to 2.23) | 3.23 (2.40 to 4.35) | −0.27 (−1.67 to 1.12) | 1.88 (1.44 to 2.44) | 1.32 (0.97 to 1.80) |
| 20–100% poverty | 53 | 239 | 1.86 (1.27 to 2.71) | 3.72 (2.80 to 4.94) | −0.04 (−1.47 to 1.40) | 1.90 (1.39 to 2.59) | 1.29 (0.92 to 1.81) |
| P Interaction | .61 | .41 | |||||
*
Military/other not estimated due to cell size. RERI = relative excess risk due to interaction; SES = socioeconomic status.
†
Adjusted for age; stage; subtype; receipt of surgery, chemotherapy, radiation, hormone therapy, and trastuzumab; insurance status.